Other large investors have also recently added to or reduced their stakes in the company. Goodman Advisory Group LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at $39,000. TD Capital Management LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at $48,000. Cowa LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter worth about $58,000. Adirondack Retirement Specialists Inc. bought a new position in shares of Johnson & Johnson during the 3rd quarter worth about $67,000. Finally, Heritage Wealth Management LLC bought a new position in Johnson & Johnson during the 2nd quarter valued at about $84,000. Institutional investors and hedge funds own 67.94% of the company’s stock.
Johnson & Johnson Stock Down 0.4 %
JNJ stock opened at $162.04 on Wednesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The business’s 50-day moving average is $172.25 and its two-hundred day moving average is $170.03. The company has a market cap of $423.65 billion, a price-to-earnings ratio of 24.04, a P/E/G ratio of 2.79 and a beta of 0.54. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.13. The business had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a return on equity of 35.94% and a net margin of 18.90%. The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.13 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.79%. Johnson & Johnson’s dividend payout ratio is currently 67.06%.
In related news, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $175.00, for a total value of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Ashley Mcevoy sold 73,323 shares of the stock in a transaction on Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total value of $12,865,986.81. Following the sale, the executive vice president now directly owns 41,813 shares in the company, valued at $7,336,927.11. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Robert J. Decker sold 16,928 shares of the stock in a transaction on Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,707,775. The disclosure for this sale can be found here. Insiders sold a total of 181,955 shares of company stock valued at $32,081,502 in the last quarter. 0.35% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on the stock. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Credit Suisse Group started coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 target price on the stock. Citigroup upped their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Finally, Piper Sandler cut their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.71.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.